Rheumatoid Arthritis MedDRA version: 14.1 Level: LLT Classification code 10066578 Term: Progression of rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 14.1 Level: LLT Classification code 10060732 Term: Rheumatoid arthritis flare up System Organ Class: 100000004859
Conditions
Interventions
Product Name: CLAZAKIZUMAB
Product Code: BMS-945429
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: CLAZAKIZUMAB
CAS Number: 1236278-28-6
Current Sponsor code: B
Sponsors
Bristol-Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening • ACR global functional status class of 1 to 3 • Documented evidence of inadequate response approved tumor necrosis factor (TNF) inhibitors. • All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening • Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1) • Elevated High-sensitivity (hs) CRP Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Active serious infection • History of or active TB • Elevated LFTs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: 1) Assess the efficacy of clazakizumab on a background of methotrexate in reducing signs and symptoms of rheumatoid arthritis by measures such as ACR rates, remission rates, and DAS28-CRP < 2.6, over 12 weeks of treatment. 2) Assess the efficacy of clazakizumab on a background of methotrexate in improving physical function as determined by change from baseline in HAQ-DI at 12 weeks of treatment. 3) Assess the safety of clazakizumab on a background of methotrexate by assessment of Adverse Events (AEs) and laboratory parameters. 4) Characterize the pharmacokinetics, immunogenicity, pharmacodynamics and biomarker responses of different clazakizumab doses on a background of methotrexate.;Main Objective: To compare the efficacy of clazakizumab versus placebo on a background of methotrexate as assessed by change from baseline in DAS28-CRP at 12 weeks;Primary end point(s): Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) change from baseline at Week 12;Timepoint(s) of evaluation of this end point: Baseline (Day 1) and Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • American College of Rheumatology (ACR) 20/50/70 Responses • Health assessment questionnaire disability index (HAQ-DI) change from baseline at Week 12 • Adverse events (AEs), and immunogenicity during the double-blind period ;Timepoint(s) of evaluation of this end point: • At week 12 • Baseline (Day 1) and Week 12 • Up to week 12 | — |
Countries
Argentina, Australia, Canada, Czech Republic, France, Hungary, Italy, Japan, Mexico, South Africa, United States
Contacts
Public ContactEU Study Start-Up Unit
Bristol-Myers Squibb International Corporation
Outcome results
None listed